Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.67 |
| ▸ | MLNR | O43193 | 1/20 | 0.67 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | MC4R | P32245 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342733 | 0.90 | CACNA2D1 (0.76) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL3592 | 0.90 | CACNA2D1 (0.76) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL521176 | 0.90 | CACNA2D1 (0.76) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL29420217 | 0.90 | CACNA2D1 (0.76) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL521869 | 0.90 | CACNA2D1 (0.76) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| Hydrochloric Acid SCHEMBL3280673 | 0.89 | CACNA2D1 (0.74) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| Hydrochloric Acid SCHEMBL3358201 | 0.89 | CACNA2D1 (0.74) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL690970 | 0.88 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL692061 | 0.88 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HTR1AMLNR | |
| SCHEMBL12719855 | 0.88 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HTR1AMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008439-A1 | DULOXETIN COMPOSITION | LEK PHARMACEUTICALS D.D. (SI) | 2011-01-13 | — | — | US | disclosed |
| US-20100280093-A1 | PROCESS FOR THE PREPARATION ENANTIOMERICALLY PURE SALTS OF N-METHYL-3-(1-NAPHTHALENEOXY)-3-(2-THIENYL)PROPANAMINE | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-04 | — | — | US | disclosed |
| US-20100280093-A1 | PROCESS FOR THE PREPARATION ENANTIOMERICALLY PURE SALTS OF N-METHYL-3-(1-NAPHTHALENEOXY)-3-(2-THIENYL)PROPANAMINE | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-04 | — | — | US | disclosed |
| US-20090226517-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING DULOXETINE | DR. REDDY'S LABORATORIES, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090221668-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM, S.A. | 2009-09-03 | — | — | US | disclosed |
| US-20090182156-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM S.A. (ES) | 2009-07-16 | — | — | US | disclosed |
| US-20090093645-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | MEDICHEM S.A. (ES) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221668-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | SLC6A2, SLC6A4, QDPR | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 8/4885 |
| US-20090226517-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING DULOXETINE | SLC6A4, SLC6A2, HTR5A | SLC6A2 2/4885SLC6A4 1/4885SLC6A3 11/4885 |
| US-20100280093-A1 | PROCESS FOR THE PREPARATION ENANTIOMERICALLY PURE SALTS OF N-METHYL-3-(1-NAPHTHALENEOXY)-3-(2-THIENYL)PROPANAMINE | PNMT, HTR3A, CHRNA3 | SLC6A2 5/4885SLC6A4 13/4885SLC6A3 8/4885 |
| US-20090182156-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885 |
| US-20110008439-A1 | DULOXETIN COMPOSITION | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885 |
| US-20090093645-A1 | SYNTHESIS AND PREPARATIONS OF DULOXETINE SALTS | SLC6A2, SLC6A4, CYP2D6 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.